171 related articles for article (PubMed ID: 9582438)
1. Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary.
Inoue A; Seto M; Sugita S; Hide I; Hirose T; Koga N; Kikuchi T; Nakata Y
Brain Res Mol Brain Res; 1998 Apr; 55(2):285-92. PubMed ID: 9582438
[TBL] [Abstract][Full Text] [Related]
2. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum.
Inoue A; Miki S; Seto M; Kikuchi T; Morita S; Ueda H; Misu Y; Nakata Y
Eur J Pharmacol; 1997 Feb; 321(1):105-11. PubMed ID: 9083792
[TBL] [Abstract][Full Text] [Related]
3. The effects of dopamine and D2 receptor antagonists on pituitary hormone secretion are intact in mice lacking dopamine D2L receptor.
Xu R; Parlow AF; Wang Y
Brain Res; 2002 Jun; 939(1-2):95-9. PubMed ID: 12020855
[TBL] [Abstract][Full Text] [Related]
4. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
5. Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor messenger RNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland.
Oomizu S; Boyadjieva N; Sarkar DK
Alcohol Clin Exp Res; 2003 Jun; 27(6):975-80. PubMed ID: 12824819
[TBL] [Abstract][Full Text] [Related]
6. Absence of D2S dopamine receptor in the prolactin-secreting MMQ pituitary clone: characterization of a wild D2L receptor coupled to native transduction mechanisms.
Ventra C; Meucci O; Grimaldi M; Scorziello A; Porcellini A; Schettini G
J Mol Endocrinol; 1995 Jun; 14(3):375-89. PubMed ID: 7669227
[TBL] [Abstract][Full Text] [Related]
7. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
[TBL] [Abstract][Full Text] [Related]
8. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland.
Inoue T; Domae M; Yamada K; Furukawa T
J Pharmacol Exp Ther; 1996 Apr; 277(1):137-43. PubMed ID: 8613910
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects.
Han M; Huang XF; Deng C
Int J Neuropsychopharmacol; 2009 Aug; 12(7):941-52. PubMed ID: 19203411
[TBL] [Abstract][Full Text] [Related]
10. Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.
Varela FA; Der-Ghazarian T; Lee RJ; Charntikov S; Crawford CA; McDougall SA
J Psychopharmacol; 2014 Apr; 28(4):376-86. PubMed ID: 24045880
[TBL] [Abstract][Full Text] [Related]
11. The effect of haloperidol on D2 dopamine receptor subtype mRNA levels in the brain.
Fishburn CS; David C; Carmon S; Fuchs S
FEBS Lett; 1994 Feb; 339(1-2):63-6. PubMed ID: 8313980
[TBL] [Abstract][Full Text] [Related]
12. [How do antipsychotics exert their effects on dopamine receptor subtypes?].
Inoue A; Nakata Y
Nihon Yakurigaku Zasshi; 1998 Dec; 112(6):351-61. PubMed ID: 10202760
[TBL] [Abstract][Full Text] [Related]
13. Haloperidol, spiperone, pimozide and aripiprazole reduce intracellular dopamine content in PC12 cells and rat mesencephalic cultures: Implication of inhibition of vesicular transport.
Matsuo T; Izumi Y; Wakita S; Kume T; Takada-Takatori Y; Sawada H; Akaike A
Eur J Pharmacol; 2010 Aug; 640(1-3):68-74. PubMed ID: 20460122
[TBL] [Abstract][Full Text] [Related]
14. Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary.
Jaber M; Tison F; Fournier MC; Bloch B
Brain Res Mol Brain Res; 1994 Apr; 23(1-2):14-20. PubMed ID: 7518029
[TBL] [Abstract][Full Text] [Related]
15. Subchronic administration of clozapine, but not haloperidol or metoclopramide, decreases dopamine D2 receptor messenger RNA levels in the nucleus accumbens and caudate-putamen in rats.
See RE; Lynch AM; Sorg BA
Neuroscience; 1996 May; 72(1):99-104. PubMed ID: 8730709
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of clozapine and haloperidol on dopamine receptor mRNA expression in rat striatum and cortex.
Damask SP; Bovenkerk KA; de la Pena G; Hoversten KM; Peters DB; Valentine AM; Meador-Woodruff JH
Brain Res Mol Brain Res; 1996 Sep; 41(1-2):241-9. PubMed ID: 8883957
[TBL] [Abstract][Full Text] [Related]
17. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
Aihara K; Shimada J; Miwa T; Tottori K; Burris KD; Yocca FD; Horie M; Kikuchi T
Brain Res; 2004 Apr; 1003(1-2):9-17. PubMed ID: 15019558
[TBL] [Abstract][Full Text] [Related]
18. Comparison of in vitro binding properties of a series of dopamine antagonists and agonists for cloned human dopamine D2S and D2L receptors and for D2 receptors in rat striatal and mesolimbic tissues, using [125I] 2'-iodospiperone.
Leysen JE; Gommeren W; Mertens J; Luyten WH; Pauwels PJ; Ewert M; Seeburg P
Psychopharmacology (Berl); 1993; 110(1-2):27-36. PubMed ID: 7870895
[TBL] [Abstract][Full Text] [Related]
19. Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors.
Centonze D; Usiello A; Costa C; Picconi B; Erbs E; Bernardi G; Borrelli E; Calabresi P
J Neurosci; 2004 Sep; 24(38):8214-22. PubMed ID: 15385604
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.
Burris KD; Molski TF; Xu C; Ryan E; Tottori K; Kikuchi T; Yocca FD; Molinoff PB
J Pharmacol Exp Ther; 2002 Jul; 302(1):381-9. PubMed ID: 12065741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
